Oruka Therapeutics (ORKA) AGM 2026 summary

Opening remarks and agenda

• The meeting was called to order by the CEO, who introduced board members, the general counsel, and representatives from the independent auditor.

• The agenda and rules of conduct were outlined, emphasizing an orderly and informative session.

• The business items to be addressed were those outlined in the proxy statement.

Board and executive committee updates

• Two Class II Director nominees, including the CEO and Chris Martin, were up for election to serve until the 2029 Annual Meeting.

Shareholder proposals

• Three proposals were presented: election of directors, ratification of the independent auditor, and a non-binding advisory vote on executive compensation.